Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK) News: Expectations Of What’s Next, Gettin’ Bond-y & More

Page 1 of 2

Editor’s Note: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Petroleo Brasileiro Petrobras SA (NYSE:PBR), American Express Company (NYSE:AXP)

Feds offer more benefits to 390 laid-off Pfizer workers (TheDay)
Nearly 400 former workers at Pfizer Inc. (NYSE:PFE), including some who were working at the Groton laboratories as contractors for ExecuPharm Inc., have been told they qualify for federal benefits after their jobs were moved overseas. The U.S. Department of Labor, in a decision released this week, said 390 workers who were laid off after Sept. 5, 2011, or who are facing job separations through Oct. 25, 2014, are eligible for so-called Trade Adjustment Assistance, which includes extended unemployment benefits, relocation payments, help with tuition and, in some cases, wage subsidies.

Pfizer Inc. (NYSE:PFE)

Pfizer’s Buy Rating Reaffirmed at TheStreet (PFE) (DailyPolitical)
TheStreet reiterated their buy rating on shares of Pfizer Inc. (NYSE:PFE) in a research note issued to investors on Wednesday, Analyst Ratings Network reports. “Pfizer Inc. (NYSE:PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”,” TheStreet’s analyst wrote. PFE has been the subject of a number of other recent research reports.

Finding the Next Big Blockbuster Drug (SECFilings)
The pharmaceutical industry is largely centered on blockbuster drugs, with the top 20 drugs in the U.S. accounting for nearly $320 billion in sales in 2011. With five of those 20 drugs losing patent protection since then, there has been a high premium placed on finding the next big blockbuster drug on the part of companies and investors in the pharmaceutical industry. …Pfizer Inc. (NYSE:PFE)’s Lipitor® is a statin that works by blocking the enzyme HMG-CoA reductase in the liver in order to lower LDL cholesterol levels. The idea for a statin didn’t come from Pfizer Inc. (NYSE:PFE) – far from it. Dr. Akira Endo discovered statins working for a small Tokyo drug company called Sankyo in 1971 after spending years searching through more than 6,000 microbes for an HMG-CoA inhibitor.

Pfizer to pick some contract manufacturers for new elevated role (FiercePharmaManufacturing)
Pfizer Inc. (NYSE:PFE) “external partner management” process is not exactly “American Idol” and Pfizer Inc. (NYSE:PFE)’s John F. Kelly is not exactly Simon Cowell, but this year the Pfizer Global Supply (PGS) unit will go through the exercise of turning a handful or two of its more than 200 contractors into stars. …Pfizer Inc. (NYSE:PFE)’s CEO Ian Read has been remaking the drug giant into a more efficient operation, selling off units and narrowing its focus to respond to the world it lives in since losing the patent on the all-time best-selling drug Lipitor.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!